Expand VSTM Menu
VSTM MENU

VSTM Latest Press Releases

-- March 4, 2026 --

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates Business Wire 4:01 PM

-- February 18, 2026 --

Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 Business Wire 7:30 AM

-- February 4, 2026 --

Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers Business Wire 7:30 AM

-- January 12, 2026 --

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- December 29, 2025 --

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer Business Wire 4:01 PM

-- December 15, 2025 --

Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth Business Wire 4:01 PM

-- November 25, 2025 --

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference Business Wire 7:30 AM

-- November 14, 2025 --

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants Business Wire 12:41 AM

-- November 13, 2025 --

Verastem Oncology Announces Proposed Public Offering of Common Stock Business Wire 4:07 PM

-- November 5, 2025 --

Verastem Oncology to Present at Upcoming Investor Conferences Business Wire 7:30 AM

-- November 4, 2025 --

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates Business Wire 7:30 AM

-- October 23, 2025 --

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors Business Wire 4:01 PM
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 Business Wire 7:30 AM

-- October 19, 2025 --

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma Business Wire 4:15 AM
Market Data Delayed 15 Minutes